TG 4040

Drug Profile

TG 4040

Alternative Names: HCV therapeutic vaccine - Transgene; Hepatitis C vaccine - Transgene; MVA-HCV; TG4040

Latest Information Update: 06 Aug 2015

Price : $50

At a glance

  • Originator Transgene
  • Class Viral hepatitis vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 28 May 2013 Intercell has merged with Vivalis to form Valneva
  • 29 Apr 2013 Efficacy, adverse events and immunogenicity data from the phase II HCVac trial in Hepatitis C presented at the 48th Annual Meeting of the European Association for the Study of the Liver (EASL-2013) ,
  • 01 Apr 2013 Transgene completes a phase II trial in Hepatitis C in Germany, France, Poland, Spain, USA and Israel (NCT01055821)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top